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Background: Bradykinin-mediated angioedema (Bk-AE) can be life-threatening and requires specific targeted
therapies. Knowledge of its epidemiology may help optimize its management.
Methods: We systematically searched the medical literature to identify abstracts of interest indexed between 1948 and
March, 2016. We used published national survey data on the proportion of the population treated with angiotensin-
converting enzyme inhibitors (ACEI) to derive estimates of the population prevalence of ACEI-AE in the USA, Germany
and France. For hereditary angioedema (C1-INH-HAE) and C1-inhibitor related acquired angioedema (C1-INH-AAE),
publications had to contain original epidemiologic data collection within a defined geographical area. Hereditary
angioedema with normal C1-INH was not included in the analysis due to lack of clearly defined criteria.
Results: We identified 4 relevant publications on the prevalence of ACEI-AE, 6 on the prevalence of C1-INH-HAE, and 1
on the prevalence of C1-INH-AAE. The 1st year cumulative incidence of ACEI-AE was estimated to vary between 0.12
(population-based analyses) and 0.30 (meta-analyses of clinical trials) per 100 patient-years. The population prevalence
of ACEI-AE was modeled to vary between 7 and 26 in 100,000. The prevalence of C1-INH-HAE was estimated to vary
between 1.1 and 1.6 per 100,000. The prevalence of C1-INH-AAE was estimated to be 0.15 per 100,000 in one
epidemiological investigation of AAE in Denmark.
Conclusions: Epidemiological evidence on Bk-AE is limited to North America and Europe. ACEI-AE is more common
than C1-INH-HAE (~ 10:1), which is more common than C1-INH-AAE (~ 10:1). More studies are needed to
comprehensively assess the epidemiological burden of Bk-AE.
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Angioedema is a swelling of the deeper layers of the
skin and mucous membranes subsequent to blood
vessel dilation and increased vascular permeability in-
duced by vasoactive mediators such as histamine and
bradykinin. Angioedema can be life-threatening when
involving the upper airways or very debilitating when
involving the gastrointestinal tract. Most cases of an-
gioedema are non-hereditary in nature [1]. A signifi-
cant share is mediated by mast-cell mediators such as
histamine, but a substantial proportion are unrelated* Correspondence: aygoeren@em.uni-frankfurt.de
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(Bk-AE). Bradykinin is a potent vasodilator, increases vas-
cular permeability, and mediates pain [2–5]. While mast
cell -mediated angioedema can be successfully treated with
antihistamines and glucocorticosteroids and with omalizu-
mab as a prophylactic treatment [6], Bk-AE requires inter-
ventions that target the synthesis or receptor activity of
bradykinin. This distinction is essential in life-threatening
situations such as swellings of the upper airways where the
use of the wrong therapy translates into unnecessary suf-
fering and the risk of suffocation.
Bk-AE results from a variety of circumstances, such as a
slow-down in bradykinin degradation subsequent to the
use of angiotensin converting enzyme inhibitor (ACEI-
AE), or the uncontrolled generation of bradykinin, such asle is distributed under the terms of the Creative Commons Attribution 4.0
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recurrent angioedema due to acquired C1-Inhibitor defi-
ciency (C1-INH-AAE) [7] (Table 1). ACE is critical in the
degradation of bradykinin, which is hypothesized to accu-
mulate excessively in some patients taking ACEI for their
hypertension. Uncontrolled generation of bradykinin, on
the other hand, occurs when complement-1 inhibitor (C1-
INH) is either deficient or non-functioning. The physio-
logical role of C1-INH is to control the generation of
bradykinin after activation of the contact system. C1-INH-
HAE is inherited as an autosomal dominant mutation that
results in low levels of C1-INH (type I) or non-functioning
C1-INH (type II). An increasing number of patients are
also reported to have Bk-AE of hereditary nature, despite
normal levels of C1-INH [8, 9]. Mutations of factor XII,
and more recently of plasminogen and angiopoietin-1 were
found in a small subgroup, but the majority lack clear de-
fining criteria [10, 11]. HAE with normal C1-INH is not
covered by our study. C1-INH-AAE is acquired as a result
of C1-INH depletion predominantly in association with
lymphoproliferative disorders.
ACEI-AE is a relatively new phenomenon that is largely
determined by the use of ACEI in the population and ap-
pears to be twice as likely in patients of African ancestry
[12]. The prevalence of C1-INH-HAE should be deter-
mined by the incidence of spontaneous mutations, the
mortality of the disease, and the average numbers of chil-
dren of C1-INH-HAE patients. In other words, a stable
prevalence would suggest equilibrium among the birth-
rates and mortality rates of patients with spontaneously
developed and familial C1-INH-HAE.
Prevalence and incidence rates of ACEI-AE and C1-
INH-HAE are frequently found in reviews that cover these
conditions. For example, the typical prevalence for C1-
INH-HAE reported is 1 in 50,000 [13, 14], although the
evidence of this has not been systematically assessed. In
the present study we report the results of a systematic re-
view of the epidemiological literature on BK-AE and make
an attempt of providing evidence-based estimates of its
expected prevalence. These estimates are critical in raising
awareness among physicians about the differential diagno-
sis and expected frequency of bradykinin-mediated angio-
edema [15] and they may help to promote the use of theTable 1 Classification of angioedema (adapted from
Craig et al. [7])
Bradykinin-Mediated Angioedema
C1-INH Deficiency / Defect C1-INH Normal
Inherited Acquired Inherited Acquired
HAE-1 & HAE-2 C1-INH-AAE HAE-3 ACEI-AE
C1-INH-AAE acquired angioedema due to C1 inhibitor deficiency, ACEI-AE
angiotensin-converting enzyme induced angioedema, HAE-1 hereditary angioedema
due to C1 inhibitor deficiency, HAE-2 hereditary angioedema due to C1 inhibitor
defect, HAE-3 hereditary angioedema with normal C1 inhibitor levelsavailable targeted treatment approaches that are required
for correct medical management of these patients.
Methods
Two separate search strategies were deployed to obtain
publications on the epidemiology of (1) ACEI-AE and
(2) C1-INH-HAE and C1-INH-AAE. The following da-
tabases were searched:
 Medline from 1948 to March (week 2) 2016
 EMBASE from 1980 to March (week 2) 2016
 The database maintained by the UK NHS Centre for
Reviews and Dissemination (CRD) (http://
www.crd.york.ac.uk/crdweb/).
The search strategy for ACEI-AE in Medline and
EMBASE was the following: exp. angioedema/ AND
(angiotensin:.tw. OR ace.tw.) AND (prevalence.tw. OR
incidence.tw. OR epidemiol:.tw.), with subsequent dedu-
plication. The search strategy for C1-INH-HAE and C1-
INH-AAE was as follows: (*Angio(o)edema/cl, ep, pc OR
(hereditary adj angio(o)edema).tw. OR *angio(o)edema,
hereditary/ OR (quincke adj angio(o)edema).tw. OR ((ac-
quired adj angio(o)edema).tw.) AND (prevalen: or inci-
den: or epidemiol:).tw. with subsequent deduplication of
references from both databases. The CRD database was
searched using the text word combination “angioedema”
and “angiotensin” for induced angioedema, and “heredi-
tary angioedema” for C1-INH-HAE.
The titles and abstracts of all references retrieved
through the searches were independently scanned by all
four authors and had to meet the following criteria to be
included: (1) For ACEI-AE the publication had to be a
systematic review of randomized controlled trials of
ACEI or an inception cohort of new ACEI users; (2) for
C1-INH-HAE or C1-INH-AAE the publication had to
contain an original epidemiologic data collection in pa-
tients with C1-INH-HAE (Type I or II) or C1-INH-
AAE, using a survey or sampling strategy that allowed a
comprehensive accounting of affected individuals within
a defined national area. Discrepancies in the assessments
of evaluators were resolved by consensus measures.
To determine the prevalence of ACEI-AE at the popula-
tion level, a subsequent literature search of Medline and
EMBASE was conducted to identify National population-
based surveys from, the US, France and Germany that
provided information about the proportion of the popula-
tion being treated with anti-hypertensives and among
those, the proportion of patients being prescribed ACEI.
Countries representative of large populations and different
proportions of ACEi use among antihypertensives were
exemplarily selected. The incidence of ACEI-AE from
systematic reviews of randomized controlled trials or
inception cohort-based epidemiological was then
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anti-hypertensives to derive population-based estimates of
the incidence or annual prevalence of ACEI-AE. This re-
search is exempt from IRB review.
Results
Estimation of the population-based prevalence of ACEI-AE
The search strategy for ACEI-AE in Medline and EMBASE
yielded the following results (Table 2):
Four relevant publications were retained from the 195
ACEI-AE-related references retrieved in Medline and
EMBASE: one study was a pooled analysis of 12 RCTs that
compared an ARB with different ACEIs from the manufac-
turer’s database [16], one was a meta-analysis of 26 US and
international randomized controlled trials of ACEI in pa-
tients with cardiovascular conditions [12, 16], one was an
analysis of new ACEI users in a Medicaid population [17]
and one was an original, population-based epidemiological
investigation of a tertiary database in the USA [18].
The search for ACEI-AE in the CRD database led
to 10 hits: meta-analyses of ACEI-AE (n = 2), meta-
analysis of ACEI for heart failure (n = 1), meta-
analyses for ACEI use in primary hypertension (n = 2),
tolerability of angiotensin receptor blockers (ARBs)
(n = 1), ACEI treatment alone vs. combination therapy
with ARBs (n = 1), ARB use in patients with ACEI-AE
(n = 1) and unrelated economic evaluations (n = 2).
One of the 2 meta-analyses of ACEI-AE found in the
CRD database was a protocol for a Cochrane system-
atic review written in 2008. Only one of the CRD
database hits was a relevant meta-analysis, and there-
fore relevant for our analyses, and this publication
was also found in the Medline/EMBASE search [12].
Individual study findings (Table 3)
The first meta-analysis was technically a pooled analysis
of 12 RCTs comparing telmisartan (n = 2564 patients)Table 2 Search strategy for ACEI-AE in Medline and EMBASE
(OVID) – 1948 to March, week 2, 2016
1 exp angioedema/ 20,520
2 angiotensin:.tw 200,463
3 ace.tw 68,287
4 2 or 3 227,296
5 1 and 4 2450
6 (prevalence or incidence or epidemiol:).tw. 2,590,164
7 5 and 6 396
8 limit 7 to review 153
9 7 not 8 243
10 limit 9 to animal 5
11 9 not 10 238
12 after removing duplicates 195with ACEI (n = 2144 patients) [16]. Angioedema were
observed in 4 patients receiving ACEI (0.2%) and no pa-
tient receiving telmisartan. The second meta-analysis
consisted of a systematic review of Pubmed/CENTRAL
and EMBASE from 1980 through Oct. 2011 to find
RCTs in patients on ACEI, ARBs or direct renin inhibi-
tors (DRIs) [12]. The authors found 26 trials with 74,857
patients on ACEI (232,523 person-years), 19 trials with
35,479 patients on ARB (122,293 person-years of follow-
up), and 2 trials with 5141 patients on DRI (1735
person-years of follow-up). The weighted incidence of
angioedema with ACE inhibitors was 0.30% (95% CI 0.
28% to 0.32%) compared to 0.11% (95% CI 0.09 to 0.13)
with ARBs, 0.13% (95% CI 0.08% to 0.19%) with DRIs,
and 0.07% with placebo (95% CI 0.05 to 0.09).
The tertiary database analysis provided estimates of
the 1st year incidence of ACEI-AE in the US Medicaid
population from Michigan, Ohio and Tennessee between
1986 and 1992 [17]. The cumulative incidence in Cauca-
sians varied between 0.9 and 1.3 per 1000 patient-years
in the three states (0.09 to 0.13%), while the incidence in
blacks varied between 2.8 and 4.2 per 1000 patient-years
(0.28 to 0.42%). The pooled incidence across whites and
blacks derived from the reported data was 1.2 per 1000
patient-years (adjusted) and 1.8 per 1000 patient-years
(unadjusted).
The fourth study provided an estimate of the
population-based incidence of ACEI-AE [18] . This was
an analysis of the Mini-Sentinel Program instituted by
the FDA to develop a national system for monitoring the
safety of medical products (2007 FDA Amendments
Act). The authors used a new user (inception cohort) de-
sign to identify patients > 18 years of age who were pre-
scribed an ACEI, ARB, DRI or beta-blocker (control
group) in a 10-year period between Jan 1, 2001 and Dec
31, 2010. The study covered a population base of
65,006,161 health plan members > 18 years old. Angio-
edema diagnoses of any severity were retained from
3301 patients among 1,845,138 exposed, with 753,105
person-years of follow up. The 365-day cumulative inci-
dence was 1.79 AE cases per 1000 patient years (0.18%).
Compared to patients on beta blockers the propensity
score adjusted hazard rate ratio for the risk of ACEI-AE
was 3.04 (95% CI: 2.81–3.27). None of the ARBs were
associated with increased hazard rate ratios vs. beta
blockers. However, the use of aliskiren, a direct renin in-
hibitor (DRI), was associated with an increased hazard
rate ratio for AE of 2.85 (95% CI: 1.34–6.04), but only
seven patients on aliskiren developed angioedema.
Thus, the 365-day cumulative prevalence of ACEI-AE
was estimated to vary between 0.12% (population-based)
and 0.30% (RCT-based).
To extrapolate the ACEI-AE incidences to the US
population, we used data collected in the National
Table 3 Tabular summary of retained studies providing estimates of the cumulative incidence of ACEI-AE
Reference Mancia & Schumacher Makani et al. Burkhart et al. Toh et al.
Region Global Global USA USA
Time period 1994–2007 1980–2011 1986–1992 2001–2010
Design Pooled analysis of 12
randomized controlled
trials of ACEI vs. ARB
from Boehringer
Ingelheim database
Syst. review of 26 randomized
trials indexed in PubMed,
CENTRAL or EMBASE,





Medicaid records, age 15+
Retrospective inception
cohort study, age 18+,
17 US health plans in
Mini-Sentinel program
Reference population 4708 patients with
hypertension, of which
2144 on ACEI
74,857 patients on ACEI,
232,532 patient-years
of follow-up




members >18y, of which
1,845,138 ACEI initiators
Angioedema Cases 4 on ACEI vs. 0 on ARB 394 on ACEI 285 on ACEI 3301 on ACEI
Diagn. criteria MedDRA v. 8.1 Adv.
event coding
As reported in original trials ICD 995.1 ICD 995.1
Calculated prevalence 0.2% or 2 per 1000
person-years
0.3% or 3 per 1000 person-years
(95% CI: 0.28% to 0.32%)
1.2 per 1000
person-years (adjusted)
1.8 per 1000 (unadjusted)
1.8 per 1000
person-years (0.18%)
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2009/10 [19, 20]. We multiplied the population-based
(0.12%) and RCT-based (0.30%) 365-day cumulative
incidence of ACEI-AE with the proportion of ACEI
use (33.3%) [20] among the adult (18y+) US popula-
tion in 2010 (235,153,929) who were estimated to
have hypertension (29.1%) and receive antihyperten-
sive treatment (76.4%) for it. Overall, between 20,891
and 52,228 patients were estimated to suffer from
ACEI-AE in the US annually, with a population
prevalence to vary between 0.7 and 1.7 per 10,000 for
2010 (Table 4).
For Germany we found two publications providing data
on the prevalence of hypertension in general as well as
treated hypertension [20] and the use of ACEI [21]. The
annual population-based prevalence of ACEI-AE was de-
rived based on a multiplication of the population-based
(0.12%) and RCT-based (0.30%) prevalence of ACEI-AETable 4 Estimated prevalence of ACEI-AE in the US, German and Fre
the use of ACEI
US (2010/11)
Description of estimate % N
Adult population (18+): 235,153,929[35]
High blood pressure (18+): 29.1% [19] 68,429,793
Treated for HBP: 76.4% [19] 52,280,362
ACEI-use among HBP treated: 33.3% [20] 17,409,361
Estimated number of patients with ACEI-AE
(low – 0.12%): 20,891
(high – 0.30%): 52,228
Population (all ages): 309,349,689[35]
Prev. (# in 10,000) of ACEI-AE in the population:
low 0.7
high 1.7with the proportion of ACEI use (45.0%) among
users of antihypertensive drugs in the adult popula-
tion of patients with hypertension (31.6%) among
which 71.8% were considered treated. The resulting
prevalence estimate was calculated to vary between 1.0
and 2.6 per 10,000 general inhabitants for the year 2011.
In comparison, Germany had the highest ACEI-AE preva-
lence. The prevalence of ACEI-AE is determined by the
extent of ACEI use in a population. Germany not only has
a relatively high proportion of treated hypertension, but
also has the highest relative share of ACEI in the treat-
ment of high blood pressure, which both might explain
our finding.
For France, the annual population-based prevalence of
ACEI-AE was derived based on a multiplication of the
population-based (0.12%) and RCT-based (0.30%) preva-
lence of angioedema in ACEI users with the proportion of
ACEI use (26.7%) [22] among users of antihypertensivench population supported by population-based estimates of
Germany (2011) France (2006/7)
% N % N
67,085,343 [36] 47,911,356 [37]
31.6% [38] 21,198,968 31.0% [22] 14,852,520
71.8% [38] 15,220,859 50.3% [22] 7,470,818
45.0% [21] 6,849,387 26.7% [39] 1,994,708
8219 2394
20,548 5984
80,219,695 [36] 61,538,322 [37]
1.0 0.4
2.6 1.0
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(31.0%) of which 50.3% were considered treated [22].
Based on these data, the annual prevalence of ACEI
induced AE in France was estimated to vary between
0.4 and 1.0 in 10,000 given the results of the French
National Health Nutrition Study (ENNS 2006–2007),
the first study using blood pressure readings taken in
a national sample of adults aged 18–74 years and
living in continental France.Estimation of the population-based prevalence of C1-INH-
HAE and C1-INH-AAE
The search strategy for C1-INH-HAE and C1-INH-AAE
(Table 5) resulted in 407 potentially relevant references
for C1-INH-HAE and C1-INH-AAE. The search of the
CRD database led to the retrieval of five HTAs:
(1) C1-inhibitor Berinert® by the All Wales
Therapeutics and Toxicology Centre (AWTTC) in
2013
(2) C1-inhibitor Cinryze® by AWTTC in 2013
(3) Icatibant Firazyr® by AWTTC in 2012
(4) Conestat alfa (Ruconest®) by the UK National
Horizon Scanning Centre (NHSC) in 2010 and
(5) Icatibant (Firazyr®) by NHSC in 2008.
No systematic reviews or published economic evalua-
tions were found. The Cochrane Library partially cross-
references the databases maintained by CRD. The same
two HTAs were identified in the Cochrane collaboration
database.
Six prospective, population-based epidemiological inves-
tigations of C1-INH-HAE published as full-length publi-
cations were found, and one prospective population-based
epidemiological investigation published as a conference
abstract. Each study is summarized below and in Table 6.Table 5 Search strategy for C1-INH-HAE and C1-INH-AAE in
Medline and EMBASE (OVID)
1 Angioedema/cl, ep, pc [Classification,
Epidemiology, Prevention & Control]
346
2 (hereditary adj angioedema).tw. or *angioedema,
hereditary/ or (quincke adj angioedema).tw.
7489
3 (hereditary adj angiooedema).tw. or *angiooedema,
hereditary/ or (quincke adj angiooedema).tw.
5797




6 (prevalen: or inciden: or epidemiol:).tw. 2,586,905
7 5 and 6 500
7 remove duplicates from 6 407Prevalence of C1-INH-HAE in Spain
This study was based on a mail-survey that was sent to
allergist and immunologist practitioners in Spain in 1999
and was subsequently followed up by telephone [23].
Hospitals and centers potentially treating patients with
C1-INH-HAE were also contacted by mail. Patients were
also referred to the investigators by the Spanish associ-
ation of patients with HAE. All patients recorded in the
registry through the various sampling approaches were
contacted by telephone between 2003 and 2004. Only
patients with Type I or II HAE confirmed by laboratory
testing were included in this study. Patients with ac-
quired C1-INH deficiency or angioedema and no func-
tional or antigenic C1-INH deficiency were excluded.
Genetic studies were conducted on approximately three
quarters of the subjects.
Four hundred and forty-four patients were identified,
belonging to 135 unrelated families. Twenty-seven pa-
tients had no family history of HAE. The authors calcu-
lated a prevalence of C1-INH-HAE of 1.09 per 100,000
inhabitants (1 in 92,000), based on a population of 40.9
million people living in Spain in 2001. The authors con-
sidered this a “minimal prevalence” given the strategy of
sampling through tertiary referral centers. The propor-
tion of asymptomatic patients who had never had an an-
gioedema episode was 13.7%. The study also identified
19 previously undiagnosed patients and four patients
who were falsely diagnosed with C1-INH-HAE, but had
other forms of angioedema.
Prevalence of C1-INH-HAE in Norway
The prevalence of C1-INH-HAE in Norway was investi-
gated using a research registry of patients with primary
immune deficiency [24]. Patients with either a suspected
or established diagnosis were entered into the registry.
The survey was conducted in 1998/1999 among all non-
psychiatric hospitals of Norway (140 departments in 60
hospitals). Questionnaires were also distributed to mem-
bers of patient and professional organizations. Reminders
were sent to non-responders. Telephone follow-up was
conducted where necessary. Diagnoses were made accord-
ing to World Health Organization criteria. Information re-
ported for patients with C1-INH deficiencies included
gender and year of birth.
Complement deficiencies were reported by 78 patients,
of whom 67 had C1-INH deficiency. Based on a popula-
tion in Norway of 4.46 million people in 1999, this
translates to a prevalence of 1.75 per 100,000 for all
complement deficiencies and a prevalence of 1.5 per
100,000 (1 in 67,000) for C1-INH deficiency.
Prevalence of C1-INH-HAE in Denmark
A comprehensive national survey of C1-INH-HAE was
conducted in Denmark in 2001, and repeated again in
Table 6 Population-based epidemiological investigations of C1-INH-HAE
Reference Roche et al. Stray-Pedersen
et al.
Bygum A Nordenfelt et al. Zanicchelli et al. Psarros et al.
Region Spain Norway Denmark Sweden Italy Greece
































Cases 444 67 76 146 983 116
Diagn.
criteria
Criteria & C1-INH Diagnosis as
per record
Criteria & C1-INH Criteria & C1-INH/C4 Criteria & C1-INH Criteria & C1-INH
Calculated
prevalence
1.10 per 100,000 /
1 in 91,162
1.50 per 100,000 /
1 in 66,597
1.38 per 100,000 /
1 in 72,671
1.56 per 100,000 /
1 in 64,028
1.51 per 100,000 /
1 in 66,284
1.07 per 100,000 /
1 in 93,235
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initiated following the establishment of a national compre-
hensive care center for patients with HAE. The recruitment
strategy targeted hospital departments, dermatologists, cen-
ters for rare diseases, patient organizations and Danish
national reference laboratories. The survey was advertised
through local and national media outlets and complemen-
ted with family interviews and examination of medical
records.
The diagnosis of C1-INH-HAE was based on functional
or antigenic values of C1-INH of less than 50% on two
separate instances, on the background of clinical symp-
toms or a family history of HAE. The authors identified
82 patients with C1-INH-HAE, comprising 77 with HAE
Type I and 5 with HAE Type II in 26 families. Eleven
patients were without affected family members. The
prevalence of C1-INH-HAE was calculated based on a
Danish population of 5.4 million inhabitants in 2009.
However, by this time two of the original 82 HAE patients
had died and four others had emigrated for a final total of
76 patients. Based on this number, the prevalence of C1-
INH-HAE in Denmark was estimated to be approximately
1.41 cases per 100,000 (1 in ~ 71,000).
The authors were confident that the calculated preva-
lence is likely to be the true prevalence of patients with
C1-INH-HAE in Denmark, given the comprehensive
sampling strategy, the consultation of the national refer-
ence laboratory, and the screening of family members.
However, they acknowledge that patients diagnosed be-
fore 1993 without any further follow-up could have been
missed by the survey.
Prevalence in Sweden
A retrospective patient survey was conducted in Sweden
to investigate the disease burden of C1-INH-HAE using
Sweha-Reg, a population-based census of C1-INH-HAE
patients [26]. All known C1-INH-HAE patients inSweden were invited to participate in the study. Patients
were contacted by the Swedish Patient Organization or
by one of the two special laboratories for complement
deficiency, or departments of internal medicine, oto-
rhinolaryngology, allergy, dermatology, or pediatrics
known to treat patients with HAE. One hundred and
forty-five patients were identified within the database as
of June 2011, leading to a calculated minimal prevalence
in Sweden of 1.51 per 100,000 (1 in 66,000), given a
population size of 9.348 Million.
Prevalence in Italy
Patients registered by the Italian network for C1-INH-
HAE (ITACA) from 17 tertiary referral practices were
included in the study [27]. Diagnosis of HAE Type 1 and
2 was made on the basis of the patient’s personal or fam-
ily history and on C1-INH functional or antigenic
plasma levels ≤50% of normal. Nine-hundred eighty
three (983) patients were identified, of which 63 had
died and 3 were missing critical information. Therefore,
the prevalence of HAE Type 1 and 2 in Italy was esti-
mated to be at least 1.51 per 100,000 (1 in 66,284) at the
end of 2013, when the Italian population consisted of
60,782,668 inhabitants.
Prevalence in Greece
A national registry of patients with HAE was initiated in
Greece in 2009 [28]. This was an extensive effort of re-
cruitment adopted by the Hellenic Society for Allergy and
Clinical Immunology. Patients recruited into the registry
between 7/2010 and 6/2013 were included in the publica-
tion. Confirmatory laboratory tests were conducted to es-
tablish the diagnosis on the basis of the International
Consensus publication. One-hundred sixteen (116) pa-
tients were identified, establishing a prevalence of 1.07 per
100,000, or 1 in 93,235 for the 2012 population of Greece,
which then had 10,815,197 inhabitants.
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Only one study provided an original estimation of the
population-based prevalence of C1-INH-AAE. This study
was undertaken in Denmark and identified eight (8) pa-
tients with C1-INH-AAE in the entire nation. According
to the authors, this number represents less than 10% of
the C1-INH-HAE patients, as there were 82 patients with
C1-INH-HAE identified in Denmark, a percentage that is
in line with a previous observation of a 1:10 ratio of C1-
INH-AAE: C1-INH-HAE [29].
Discussion
We summarized the studies reporting on the annual
prevalence of ACEI-AE, and prevalence of C1-INH-
HAE and C1-INH-AAE. The prevalence of ACEI-AE
is determined by the country-specific use of antihy-
pertensive; in the US, the prevalence was estimated to
vary between 0.7 and 1.7 per 10,000 inhabitants when
weighting the risk of ACEI-AE among Caucasians and
African-Americans. In Germany it was estimated to
vary between 1.0 and 2.6 per 10,000 while in France
it was estimated to be lower and vary between 0.4
and 1.0 in 10,000. The prevalence of C1-INH-HAE
was estimated to vary between 1.1 and 1.6 per
100,000. The prevalence of C1-INH-AAE was esti-
mated to be 1.5 per 1 Million from the one available
epidemiological investigation of C1-INH-AAE in
Denmark.
Overall, the prevalence figures would be approximately 1.
5 per 10,000 for ACEI-AEs, 1.5 per 100,000 for C1-INH-
HAE and 1.5 per 1 Million for C1-INH-AAE. For every
100 patients with ACEI-AE there would be 10 patients with
C1-INH-HAE and 1 patient with C1-INH-AAE. However,
patients with C1-INH-HAE have on average 1 angioedema
attack per month [25]. For this reason, the number of an-
nual angioedema attacks due to C1-INH-HAE and ACEI
use should be similar, given that ACEI are typically with-
drawn at the time of diagnosis and re-occurrence is less
likely. For a country with 100 Million inhabitants there
would be approximately 31,500 bradykinin mediated angio-
edema attacks each year, calculated by multiplying the
prevalence standardized to 1 million, 150 for ACEI-AE, 15
per for C1-INH-HAE, and 1.5 for C1-INH-AAE, with 100
for each entity, and multiplying the resulting figures with
an annual attack rate of approximately 1 per year for ACEI-
AE and 10/year for C1-INH-HAE and C1-INH-AAE.
Treatments for histamine-mediated angioedema are in-
appropriate for bradykinin-mediated angioedema. These
numbers highlight the significant need to recognize the
nature of the underlying cause in each patient who repre-
sents to the emergency room with signs and symptoms of
an angioedema attack.
In the absence of confirmatory investigations, many
publications referenced the prevalence of C1-INH-HAEto be 1 in 10,000 to 1 in 50,000. Several studies have
now reported the population-based prevalence of C1-
INH-HAE. These studies were supported by intense
efforts of patient societies and providers to register pa-
tients in order to provide access to adequate treatment
and also to raise awareness and shorten the delay to a
correct diagnosis. We have summarized these studies
and determined that the prevalence of diagnosed cases
of C1-INH-HAE is approximately 1.5 per 100,000 (or ~
1 in 67,000).
A population-based estimate of ACEI-AEs has not
been published before. The annual (1st-year) cumula-
tive incidence of angioedema among ACEI users is
fairly stable, as the meta-analyses of the randomized
controlled trials and the database analyses suggest.
However, the population-based prevalence is neces-
sarily variable and depends on the actual use of
ACEI in the population, how this use was measured,
and the demographic mix, especially with respect to
the representation of African-Americans. For this
reason we were only able to provide approximate es-
timates with potentially large variation. Other antihy-
pertensives addressing the renin-angiotensin system
such as angiotensin-receptor blockers or direct renin
inhibitors have not been conclusively linked to in-
creased risk of AE. Any incremental risk of AE in
users of such drugs would translate into a higher
prevalence in the population. Also, because the ratio
of patients with ACEI-AE vs. C1-INH-HAE is ap-
proximately 10:1, we calculated that the expected
number of angioedema attacks is similar, due to the
frequency of attacks among C1-INH-HAE patients.
We searched both the Medline and EMBASE database
using appropriate keywords to select epidemiological in-
vestigations and systematic reviews. A cross-check of the
CRD database confirmed that no systematic reviews of
ACEI were missed. The C1-INH-HAE-associated litera-
ture is not as extensive as can be seen from the overall
number of search hits, because the disease is rare and is
covered by a small community of researchers. Because
there were not so many publications, we did not attempt
to quantitatively combine the estimates, but rather de-
scribe each individual study. This will enable the readers
to come to their own conclusion regarding the mani-
fested prevalence of C1-INH-HAE or ACEI-AE in their
own setting.
It appears that the epidemiology of C1-INH-HAE is
stable across the geographic regions covered in this re-
view. This may be the result of a stable mix of spontan-
eous mutations and inherited patterns [30, 31]. It is
likely that the prevalence of 1 in 67,000 provides a refer-
ence ceiling to the estimation of diagnosed patients with
C1-INH-HAE in a specific country, given the current
pattern of detection in countries with modern healthcare
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policymakers in estimating the number of patients ex-
pected in their constituencies. Moreover, as investiga-
tions of family members of affected patients have shown
[32], there still persists a percentage of undiagnosed
family members. Further efforts in raising disease aware-
ness, educating providers and improving access to ap-
propriate therapies may shorten the current lagtime of
10 [33] to 16 [25] years between onset of first symptoms
and date of diagnosis.
There are several potential clinical implications of our
results: ACEI-AE may currently be underdiagnosed in
some populations. Up until 2017, the German national
database on suspected adverse drug reactions listed
about 2000 angioedema incidents in connection with
ACEI use while prescription rates of ACEI-AE suggest a
considerably larger number [34]. This points to a gap in
the diagnosis of angioedema among ACEI users and
highlights the need for expanding the knowledge on
clinical findings, course and potential therapy of acute
ACEI-AE in the medical community. Vice versa, there
are factors that promote potential misdiagnosis of
C1INH deficiency cases as ACEI-AE cases: ACEI use is
quite common in many populations, At the same time,
ACEI are a common precipitating factor of acute angio-
edema in patients with C1-INH deficiency. In undiag-
nosed C1-INH deficiency cases, an angioedema episode
in the presence of ACEI therapy would most likely be at-
tributed to the ACEI. This might lead to a, probably
minor, effect on prevalence numbers of C1-INH-HAE
and C1-INH-AAE. The recognition of an ACEI-AE
should prompt the exclusion of C1-INH deficiency as in
diagnosed C1-INH deficiency cases investigation of fam-
ily members is warranted. To characterize clinical differ-
ences in these different entities more deeply is an unmet
need and will be the goal of future efforts.
Limitations of the study include its inherent restriction
to US and European data, while the epidemiology of Bk-
AE might be different in other parts of the world. Also,
the prevalence of ACEI-AE may be higher as estimated
in our analysis as in some of the studies patients with
previous angioedema were excluded [12, 18]. A few trials
did not report incidence of angioedema, as adverse ef-
fects were only reported if the incidence was > 1% [12].
Another limitation is the low number of prevalence
studies in Europe, for example but not restricted to
Germany and France that a lack systematic nationwide
data collection. Additionally, the present analysis is fo-
cused on ACEI-AE and C1-INH-HAE. Further efforts to
assess the epidemiology of additional types of HAE with
normal C1-INH, for example HAE due to a FXII muta-
tion (FXII-HAE), are needed. It has yet to be determined
if angioedema attacks in patients with HAE due to a
novel plasminogen mutation (HAE-PLG), HAE with anovel angiopoietin-1 gene mutation (ANGPT-1-HAE) or
HAE of unknown origin (U-HAE) are bradykinin medi-
ated, in which case future analysis of Bk-AE epidemi-
ology should include these novel types. A further
limitation of the present analysis might be the fact that
the studies indentified essentially covered the last two
decades. As awareness of Bk-AE increased considerably
over time, there is a chance that older prevalence data
may underestimate the real prevalence. Continued ef-
forts in assessing the prevalence of Bk-AE are therefore
warranted.
Conclusion
Epidemiological evidence on Bk-AE is largely limited to
North America and Europe. ACEI-AE is more common
than C1-INH-HAE (10:1), which is more common than
C1-INH-AAE (10:1). More studies are needed to compre-
hensively assess the epidemiological burden of Bk-AE.
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